Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Disposables market to reach $55 billion by 2004:

This article was originally published in Clinica

Executive Summary

US demand for disposable medical supplies is set to increase 5.3% a year up to 2004, to over $55 billion, according to a new study. The US Disposable Medical Supplies report from the Cleveland, Ohio-based market research company, The Freedonia Group, concludes that hospitals will remain the largest market. However, home healthcare is the fastest growing sector, given the move towards increased preventive medicine and self-treatment in the light of high insurance co-payments. For more details of the 371-page, $3,800 report, contact Freedonia in the US. Tel: +1 440 684 9600. Fax: +1 440 646 0484. E-mail:

You may also be interested in...

Vemedia Acquires GSK Brands In Italy, Strikes Deal For GI Product In Spain

GSK has offloaded a further two brands, this time in Italy, giving Netherlands-based Vemedia the opportunity to bolster its portfolio in the country. Vemedia has also added to its offering in Spain by striking a separate deal with Puerto Galiano.

EU Preserves Status Quo On Drugs Under Additional Monitoring

The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.

Meitheal Gets US Enoxaparin Approval

Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts